(BBOT) BridgeBio Oncology - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 706m USD | Total Return: -14.5% in 12m
Avg Turnover: 3.67M
Warnings
Share dilution 240.4% YoY
Altman Z'' -12.85 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biotechnology firm focused on developing small-molecule inhibitors for RAS and PI3K-driven malignancies. The company’s pipeline includes BBO-8520, a direct KRASG12C inhibitor, and BBO-11818, a pan-KRAS inhibitor, both currently in Phase I clinical trials. Additionally, BBOT is advancing BBO-10203 for the treatment of HER2+ breast cancer and various KRAS-mutant solid tumors.
The company operates within the precision oncology sector, which utilizes genomic profiling to target specific molecular drivers of cancer rather than using broad-spectrum chemotherapy. Developing small-molecule therapeutics involves high research and development costs, often requiring several years of clinical testing before reaching potential commercialization.
Investors looking for deeper fundamental analysis of biotechnology assets may find ValueRay a useful resource for further research. Headquartered in South San Francisco, BBOT continues to prioritize its oral bioavailability platform to improve patient outcomes in genetically defined cancers.
- Clinical trial data readouts for BBO-8520 target KRASG12C mutant lung cancer
- Phase I progress of pan-KRAS inhibitor BBO-11818 expands addressable oncology market
- Regulatory approval pathways for BBO-10203 impact long-term valuation in breast cancer
- R&D expenditure and cash runway determine timeline for clinical-stage pipeline development
- Strategic partnerships and licensing agreements for precision oncology assets drive capital inflows
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.41 > 0.02 and ΔFCF/TA -14.55 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.41 > 3% & CFO -172.1m > Net Income -154.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (80.0m) vs 12m ago 240.4% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.53 (Total Current Assets 266.5m - Total Current Liabilities 43.3m) / Total Assets 417.6m |
| B: -0.95 (Retained Earnings -398.7m / Total Assets 417.6m) |
| C: -0.60 (EBIT TTM -168.9m / Avg Total Assets 283.7m) |
| D: -8.81 (Book Value of Equity -399.6m / Total Liabilities 45.4m) |
| Altman-Z'' = -12.85 = D |
As of May 24, 2026, the stock is trading at USD 8.55 with a total of 746,267 shares traded.
Over the past week, the price has changed by +0.47%,
over one month by -3.61%,
over three months by -15.76% and
over the past year by -14.50%.
BridgeBio Oncology has no consensus analysts rating.
Revenue TTM = 0.0 USD
EBIT TTM = -168.9m USD
EBITDA TTM = -168.1m USD
Long Term Debt = 2.11m USD (estimated: total debt 2.64m - short term 538k)
Short Term Debt = 538k USD (from shortTermDebt, last quarter)
Debt = 2.64m USD (from shortLongTermDebtTotal, last quarter) (leases 2.64m already included)
Net Debt = -249.6m USD (calculated: Debt 2.64m - CCE 252.3m)
Enterprise Value = 456.1m USD (705.7m + Debt 2.64m - CCE 252.3m)
Interest Coverage Ratio = unknown (Ebit TTM -168.9m / Interest Expense TTM 0.0)
EV/FCF = -2.64x (Enterprise Value 456.1m / FCF TTM -172.9m)
FCF Yield = -37.91% (FCF TTM -172.9m / Enterprise Value 456.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 610k) / Revenue TTM)
Tobins Q-Ratio = 1.09 (Enterprise Value 456.1m / Total Assets 417.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.64m)
Taxrate = 21.0% (US default 21%)
NOPAT = -133.4m (EBIT -168.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.16 (Total Current Assets 266.5m / Total Current Liabilities 43.3m)
Debt / Equity = 0.01 (Debt 2.64m / totalStockholderEquity, last quarter 372.3m)
Debt / EBITDA = 1.48 (negative EBITDA) (Net Debt -249.6m / EBITDA -168.1m)
Debt / FCF = 1.44 (negative FCF - burning cash) (Net Debt -249.6m / FCF TTM -172.9m)
Total Stockholder Equity = 250.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -54.31% (Net Income -154.1m / Total Assets 417.6m)
RoE = -23.73% (Net Income TTM -154.1m / Total Stockholder Equity 649.3m)
RoCE = -25.92% (EBIT -168.9m / Capital Employed (Equity 649.3m + L.T.Debt 2.11m))
RoIC = -36.11% (negative operating profit) (NOPAT -133.4m / Invested Capital 369.4m)
WACC = 11.09% (E(705.7m)/V(708.4m) * Re(11.13%) + D(2.64m)/V(708.4m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 68.03 | Cagr: 83.25%
[DCF] Fair Price = unknown (Cash Flow -172.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.54 | Chg30d=-3.63% | Revisions=-25% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.56 | Chg30d=-4.45% | Revisions=-43% | Analysts=8
EPS current Year (2026-12-31): EPS=-2.22 | Chg30d=-7.58% | Revisions=-56% | GrowthEPS=+48.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.14 | Chg30d=-4.56% | Revisions=-50% | GrowthEPS=+3.7% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -56%